Skip to content
Study details
Enrolling now

Oral Cannabidiol for Tobacco Cessation

Johns Hopkins University
NCT IDNCT05445804ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

50

Study length

about 3.3 years

Ages

18–65

Locations

1 site in MD

About this study

Researchers are testing whether oral cannabidiol helps people quit smoking. The trial will see if cannabidiol increases short-term tobacco abstinence and explore how it might change smoking behavior. This is a Phase 1 trial with adults, aiming to enroll about 50 participants over 1188 days.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take 300 mg Cannabidiol
  • 2.Take 600 mg Cannabidiol
  • 3.Take Placebo
PhasePhase 1
Drug300 mg Cannabidiol
Routeoral

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low11%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

cannabidiol

Drug routes

oral (Oral Solution)

Endpoints

Secondary: Tobacco Withdrawal as assessed by the Hospital Anxiety and Depression Scale